The bruised faces of healthcare workers have become a badge of courage, the price they are willing to pay for wearing respirators, masks, and other personal protective equipment over long work shifts caring for COVID-19 patients.
The Food and Drug Administration’s guidance on conducting clinical trials during the pandemic provides reassurance that IRBs and research organizations can employ flexibility as they make changes to accommodate a world in which many patient visits are conducted remotely. The guidance does not change or modify existing regulations, but synthesizes existing regulations and emphasizes the built-in flexibility.
The NYU Grossman School of Medicine’s working group on Pediatric Gene Therapy and Medical Ethics formed in the fall of 2019 to address and propose recommendations to issues involving gene-based therapies in pediatric populations, including research activities.
The recommended care of a patient with COVID-19 is similar to what is required for other viral pneumonias, such as those associated with influenza or respiratory syncytial virus. Further, mild disease does not necessarily require hospitalization.
Simply reducing the number of opioid prescriptions is not enough, the report authors wrote. Hospitals must be much more proactive in identifying patients with opioid use disorder and initiating treatment wherever those patients are encountered within the treatment process.
A new committee opinion issued by the American College of Obstetricians and Gynecologists, in conjunction with the Women’s Preventive Services Initiative’s rollout of a “Well-Woman Chart,” is designed to help clinicians follow the latest updates for preventive care.